NextGen-O2k · Project

Multi-Sensor Lab Instrument That Reveals How Well Your Cells Produce Energy

healthMarket-readyTRL 8

Imagine your cells have tiny power plants called mitochondria. When these break down, you get diseases like diabetes, cancer, or Alzheimer's. The problem is that current lab instruments can only measure one thing at a time and give inconsistent results between labs. Oroboros built a compact device that measures multiple energy parameters simultaneously with much better accuracy — like upgrading from a single thermometer to a full diagnostic dashboard for cellular health.

By the numbers

company consortium — sole SME developer and commercializer

100%

industry ratio in consortium

total project deliverables completed

2021

target year for market launch

The business problem

What needed solving

Current lab instruments for studying how cells produce energy are limited — they measure only one parameter at a time, require multiple separate devices, and produce results that often cannot be reproduced across different laboratories. This wastes experimental time, samples, and funding, while slowing progress in understanding diseases like diabetes, cancer, and neurodegeneration where cellular energy dysfunction plays a central role.

The solution

What was built

A compact multi-sensor instrument platform (NextGen-O2k) that measures multiple bioenergetic parameters simultaneously with superior resolution and reproducibility. The project delivered 4 deliverables including an updated commercial website with a dedicated product section, indicating market-readiness preparation.

Audience

Who needs this

Pharmaceutical companies screening drugs for mitochondrial toxicityAlgae biotech companies optimizing biomass and metabolite productionContract research organizations offering standardized bioenergetic assaysUniversity core facilities upgrading their respirometry equipmentClinical research labs studying metabolic diseases like diabetes and cancer

Business applications

Who can put this to work

Pharmaceutical & Drug Discovery

enterprise

Target: Pharma companies developing treatments for mitochondrial dysfunction, neurodegenerative diseases, diabetes, or cancer

If you are a pharma R&D team screening drug candidates for mitochondrial toxicity — this project developed a multi-sensor platform that measures multiple bioenergetic parameters in one compact device. It promises superior resolution and reproducibility compared to existing instruments, meaning your results hold up across different labs and reduce failed replication. This directly cuts experimental time and sample costs during preclinical testing.

Algae Biotechnology

SME

Target: Biotech companies producing algae-based biomass, biofuels, or high-value metabolites

If you are a biotech company optimizing algal growth rates and metabolite production — this project built a device that monitors both mitochondrial and chloroplast function in real time. Instead of running separate experiments with different instruments, you get integrated bioenergetic pathway data from one platform. This means faster optimization cycles for your algae production processes.

Contract Research & Clinical Diagnostics

mid-size

Target: CROs and diagnostic labs offering mitochondrial fitness assays

If you are a contract research organization running bioenergetic assays for multiple clients — this project addressed the reproducibility crisis head-on with a device designed for consistent inter-laboratory results. A compact, affordable multi-sensor platform lets you offer standardized mitochondrial fitness testing at scale, reducing the need for repeated validation runs across sites.

Frequently asked

Quick answers

What does this instrument cost compared to existing solutions?

Specific pricing is not disclosed in the project data. However, the objective explicitly describes NextGen-O2k as 'compact and affordable,' positioning it below the cost of assembling multiple separate instruments to measure the same parameters. Contact Oroboros Instruments directly for commercial pricing.

Is this ready for industrial-scale use or still a lab concept?

This was funded under SME Instrument Phase 2, which specifically targets commercialization. The stated goal was to complete development and prepare market launch in 2021. The project closed in October 2021, indicating the instrument should be commercially available or near-commercial from Oroboros Instruments.

What is the IP and licensing situation?

Oroboros Instruments GmbH is the sole consortium partner and coordinator, meaning all IP from this project stays within the company. As a private commercial entity, they sell instruments directly. No university or research institute co-owns the results.

What exactly does this device measure that existing tools cannot?

NextGen-O2k integrates several sensors into one platform to detect multiple key bioenergetic parameters simultaneously — covering both mitochondrial and chloroplast function. Current technologies provide segmented information requiring separate instruments. The key differentiator is superior resolution and inter-laboratory reproducibility.

When was this expected to reach the market?

The project objective stated a market launch target of 2021. The project ran from June 2019 to October 2021, which aligns with completing development and preparing commercial availability. Oroboros Instruments has been selling respirometry instruments since the 1990s, so they have established distribution channels.

Who can I contact to learn more or purchase?

Oroboros Instruments GmbH in Innsbruck, Austria is the sole developer and commercial entity behind this instrument. Their project website at oroboros.at has a dedicated NextGen-O2k section. SciTransfer can facilitate a direct introduction to the commercial team.

Consortium

Who built it

This is a single-company project: Oroboros Instruments GmbH from Austria, an established SME that already manufactures and sells respirometry instruments worldwide. The 100% industry composition with zero academic partners is unusual but signals a clear commercial focus — this is not a research exploration but a product development effort. The SME Instrument Phase 2 funding confirms EU confidence in their commercialization plan. For a buyer, this means you deal directly with the manufacturer, with no complex multi-partner IP negotiations.

OROBOROS INSTRUMENTS GmbHCoordinator · AT

How to reach the team

Oroboros Instruments GmbH, Innsbruck, Austria — established instrument manufacturer with commercial sales team

Order a report on this consortium See OROBOROS INSTRUMENTS GmbH profile →

Next steps

Talk to the team behind this work.

Want an introduction to the Oroboros commercial team or a technical comparison with your current bioenergetics instruments? SciTransfer can arrange a direct conversation.

Order a report on this topic More in Health & Biomedical